

= Diffuse panbronchiolitis =

Diffuse panbronchiolitis ( DPB ) is an inflammatory lung disease of unknown cause . It is a severe , progressive form of bronchiolitis , an inflammatory condition of the bronchioles ( small air passages in the lungs ) . The term diffuse signifies that lesions appear throughout both lungs , while panbronchiolitis refers to inflammation found in all layers of the respiratory bronchioles ( those involved in gas exchange ) . DPB causes severe inflammation and nodule @-@ like lesions of terminal bronchioles , chronic sinusitis , and intense coughing with large amounts of sputum production .

The disease is believed to occur when there is susceptibility , or a lack of immune system resistance , to DPB @-@ causing bacteria or viruses , caused by several genes that are found predominantly in individuals of East Asian descent . The highest incidence occurs among Japanese people , followed by Koreans . DPB occurs more often in males , and usually begins around age 40 . It was recognized as a distinct new disease in the early 1960s , and was formally named diffuse panbronchiolitis in 1969 .

If left untreated , DPB progresses to bronchiectasis , an irreversible lung condition that involves enlargement of the bronchioles , and pooling of mucus in the bronchiolar passages . Daily treatment of DPB with macrolide antibiotics such as erythromycin eases symptoms and increases survival time , but the disease currently has no known cure . The eventual result of DPB can be respiratory failure and heart problems .

= = Classification = =

The term " bronchiolitis " generally refers to inflammation of the bronchioles . DPB is classified as a form of " primary bronchiolitis " , which means that the underlying cause of bronchiolitis is originating from or is confined to the bronchioles . Along with DPB , additional forms of primary bronchiolitis include bronchiolitis obliterans , follicular bronchiolitis , respiratory bronchiolitis , mineral dust airway disease , and a number of others . Unlike DPB , bronchiolitis that is not considered " primary " would be associated with diseases of the larger airways , such as chronic bronchitis .

= = Signs and symptoms = =

Symptoms of DPB include chronic sinusitis ( inflamed paranasal sinuses ) , wheezing , crackles ( respiratory sounds made by obstructions such as phlegm and secretions in the lungs ) , dyspnea ( shortness of breath ) , and a severe cough that yields large amounts of sputum ( coughed @-@ up phlegm ) . There may be pus in the sputum , and affected individuals may have fever . Typical signs of DPB progression include dilation ( enlargement ) of the bronchiolar passages and hypoxemia ( low levels of oxygen in the blood ) . If DPB is left untreated , bronchiectasis will occur ; it is characterized by dilation and thickening of the walls of the bronchioles , inflammatory damage to respiratory and terminal bronchioles , and pooling of mucus in the lungs . DPB is associated with progressive respiratory failure , hypercapnia ( increased levels of carbon dioxide in the blood ) , and can eventually lead to pulmonary hypertension ( high blood pressure in the pulmonary vein and artery ) and cor pulmonale ( dilation of the right ventricle of the heart , or " right heart failure " ) .

= = Cause = =

DPB is idiopathic , which means an exact physiological , environmental , or pathogenic cause of the disease is unknown . However , several factors are suspected to be involved with its pathogenesis ( the way in which the disease works ) .

The major histocompatibility complex ( MHC ) is a large genomic region found in most vertebrates that is associated with the immune system . It is located on chromosome 6 in humans . A subset of MHC in humans is human leukocyte antigen ( HLA ) , which controls the antigen @-@ presenting system , as part of adaptive immunity against pathogens such as bacteria and viruses . When

human cells are infected by a pathogen , some of them can present parts of the pathogen 's proteins on their surfaces ; this is called " antigen presentation " . The infected cells then become targets for types of cytotoxic T @-@ cells , which kill the infected cells so they can be removed from the body .

Genetic predisposition for DPB susceptibility has been localized to two HLA haplotypes ( a nucleotide or gene sequence difference between paired chromosomes , that is more likely to occur among a common ethnicity or trait ) common to people of East Asian descent . HLA @-@ B54 is associated with DPB in the Japanese , while HLA @-@ A11 is associated with the disease in Koreans . Several genes within this region of class I HLA are believed to be responsible for DPB , by allowing increased susceptibility to the disease . The common genetic background and similarities in the HLA profile of affected Japanese and Korean individuals were considered in the search for a DPB gene . It was suggested that a mutation of a suspected disease @-@ susceptibility gene located somewhere between HLA @-@ B and HLA @-@ A had occurred on an ancestral chromosome carrying both HLA @-@ B54 and HLA @-@ A11 . Further , it is possible that a number of genetic recombination events around the disease locus ( location on a chromosome ) could have resulted in the disease being associated with HLA @-@ B54 in the Japanese and HLA @-@ A11 in Koreans . After further study , it was concluded that a DPB susceptibility gene is located near the HLA @-@ B locus at chromosome 6p21.3. Within this area , the search for a genetic cause of the disease has continued .

Because many genes belonging to HLA remain unidentified , positional cloning ( a method used to identify a specific gene , when only its location on a chromosome is known ) has been used to determine that a mucin @-@ like gene is associated with DPB . In addition , diseases caused by identified HLA genes in the DPB @-@ susceptibility region have been investigated . One of these , bare lymphocyte syndrome I ( BLS I ) , exhibits a number of similarities with DPB in those affected , including chronic sinusitis , bronchiolar inflammation and nodules , and the presence of H. influenzae . Also like DPB , BLS I responds favorably to erythromycin therapy by showing a resolution of symptoms . The similarities between these two diseases , the corresponding success with the same mode of treatment , and the fact that the gene responsible for BLS I is located within the DPB @-@ causing area of HLA narrows the establishment of a gene responsible for DPB . Environmental factors such as inhaling toxic fumes and cigarette smoking are not believed to play a role in DPB , and unknown environmental and other non @-@ genetic causes ? such as unidentified bacteria or viruses ? have not been ruled out .

Cystic fibrosis ( CF ) , a progressive multi @-@ system lung disease , has been considered in the search for a genetic cause of DPB . This is for a number of reasons . CF , like DPB , causes severe lung inflammation , abundant mucus production , infection , and shows a genetic predominance among Caucasians of one geographic group to the rarity of others ; whereas DPB dominates among East Asians , CF mainly affects individuals of European descent . While no gene has been implicated as the cause of DPB , mutation in a specific gene ? much more likely to occur in Europeans ? causes CF . This mutation in the CF @-@ causing gene is not a factor in DPB , but a unique polymorphism ( variation ) in this gene is known to occur in many Asians not necessarily affected by either disease . It is being investigated whether this gene in any state of mutation could contribute to DPB .

= = Pathophysiology = =

Inflammation is a normal part of the human immune response , whereby leukocytes ( white blood cells ) , including neutrophils ( white blood cells that specialize in causing inflammation ) , gather , and chemokines ( proteins released from certain cells , which activate or elicit a response from other cells ) accumulate at any location in the body where bacterial or viral infections occur . Inflammation interferes with the activity of bacteria and viruses , and serves to clear them from the body . In DPB , bacteria such as Haemophilus influenzae and Pseudomonas aeruginosa can cause the proliferation of inflammatory cells into the bronchiolar tissues . However , when neither bacteria are present with DPB , the inflammation continues for an as yet unknown reason . In either circumstance , inflammation in DPB can be so severe that nodules containing inflammatory cells form in the walls of

the bronchioles . The presence of inflammation and infection in the airways also results in the production of excess mucus , which must be coughed up as sputum . The combination of inflammation , nodule development , infection , mucus , and frequent cough contributes to the breathing difficulties in DPB .

The fact that inflammation in DPB persists with or without the presence of *P. aeruginosa* and *H. influenzae* provides a means to determine several mechanisms of DPB pathogenesis . Leukotrienes are eicosanoids , signaling molecules made from essential fatty acids , which play a role in many lung diseases by causing the proliferation of inflammatory cells and excess mucus production in the airways . In DPB and other lung diseases , the predominant mediator of neutrophil @-@ related inflammation is leukotriene B<sub>4</sub> , which specializes in neutrophil proliferation via chemotaxis ( the movement of some types of cells toward or away from certain molecules ) .

Inflammation in DPB is also caused by the chemokine MIP @-@ 1α and its involvement with CD8 + T cells . Beta defensins , a family of antimicrobial peptides found in the respiratory tract , are responsible for further inflammation in DPB when a pathogen such as *P. aeruginosa* is present . If present with DPB , the human T @-@ lymphotropic virus , type I , a retrovirus , modifies DPB pathogenesis by infecting T helper cells and altering their effectiveness in recognizing the presence of known or unknown pathogens involved with DPB .

= = Diagnosis = =

The diagnosis of DPB requires analysis of the lungs and bronchiolar tissues , which can require a lung biopsy , or the more preferred high resolution computed tomography ( HRCT ) scan of the lungs . The diagnostic criteria include severe inflammation in all layers of the respiratory bronchioles and lung tissue lesions that appear as nodules within the terminal and respiratory bronchioles in both lungs . The nodules in DPB appear as opaque lumps when viewed on X @-@ rays of the lung , and can cause airway obstruction , which is evaluated by a pulmonary function test , or PFT . Lung X @-@ rays can also reveal dilation of the bronchiolar passages , another sign of DBP . HRCT scans often show blockages of some bronchiolar passages with mucus , which is referred to as the " tree @-@ in @-@ bud " pattern . Hypoxemia , another sign of breathing difficulty , is revealed by measuring the oxygen and carbon dioxide content of the blood , using a blood test called arterial blood gas . Other findings observed with DPB include the proliferation of lymphocytes ( white blood cells that fight infection ) , neutrophils , and foamy histiocytes ( tissue macrophages ) in the lung lining . Bacteria such as *H. influenzae* and *P. aeruginosa* are also detectable , with the latter becoming more prominent as the disease progresses . The white blood , bacterial and other cellular content of the blood can be measured by taking a complete blood count ( CBC ) . Elevated levels of IgG and IgA ( classes of immunoglobulins ) may be seen , as well as the presence of rheumatoid factor ( an indicator of autoimmunity ) . Hemagglutination , a clumping of red blood cells in response to the presence of antibodies in the blood , may also occur . Neutrophils , beta @-@ defensins , leukotrienes , and chemokines can also be detected in bronchoalveolar lavage fluid injected then removed from the bronchiolar airways of individuals with DPB , for evaluation .

= = Differential diagnosis = =

In the differential diagnosis ( finding the correct diagnosis between diseases that have overlapping features ) of some obstructive lung diseases , DPB is often considered . A number of DPB symptoms resemble those found with other obstructive lung diseases such as asthma , chronic bronchitis , and emphysema . Wheezing , coughing with sputum production , and shortness of breath are common symptoms in such diseases , and obstructive respiratory functional impairment is found on pulmonary function testing . Cystic fibrosis , like DPB , causes severe lung inflammation , excess mucus production , and infection ; but DPB does not cause disturbances of the pancreas nor the electrolytes , as does CF , so the two diseases are different and probably unrelated . DPB is distinguished by the presence of lesions that appear on X @-@ rays as nodules in the bronchioles of both lungs ; inflammation in all tissue layers of the respiratory bronchioles ; and its higher

prevalence among individuals with East Asian lineage .

DPB and bronchiolitis obliterans are two forms of primary bronchiolitis . Specific overlapping features of both diseases include strong cough with large amounts of often pus @-@ filled sputum ; nodules viewable on lung X @-@ rays in the lower bronchi and bronchiolar area ; and chronic sinusitis . In DPB , the nodules are more restricted to the respiratory bronchioles , while in OB they are often found in the membranous bronchioles ( the initial non @-@ cartilaginous section of the bronchiole , that divides from the tertiary bronchus ) up to the secondary bronchus . OB is a bronchiolar disease with worldwide prevalence , while DPB has more localized prevalence , predominantly in Japan . Prior to clinical recognition of DPB in recent years , it was often misdiagnosed as bronchiectasia , COPD , IPF , phthisis miliaris , sarcoidosis or alveolar cell carcinoma .

= = Treatment = =

Macrolide antibiotics , such as erythromycin , are an effective treatment for DPB when taken regularly over an extended period of time . Clarithromycin or roxithromycin are also commonly used . The successful results of macrolides in DPB and similar lung diseases stems from managing certain symptoms through immunomodulation ( adjusting the immune response ) , which can be achieved by taking the antibiotics in low doses . Treatment consists of daily oral administration of erythromycin for two to three years , an extended period that has been shown to dramatically improve the effects of DPB . This is apparent when an individual undergoing treatment for DPB , among a number of disease @-@ related remission criteria , has a normal neutrophil count detected in BAL fluid , and blood gas ( an arterial blood test that measures the amount of oxygen and carbon dioxide in the blood ) readings show that free oxygen in the blood is within the normal range . Allowing a temporary break from erythromycin therapy in these instances has been suggested , to reduce the formation of macrolide @-@ resistant *P. aeruginosa* . However , DPB symptoms usually return , and treatment would need to be resumed . Although highly effective , erythromycin may not prove successful in all individuals with the disease , particularly if macrolide @-@ resistant *P. aeruginosa* is present or previously untreated DPB has progressed to the point where respiratory failure is occurring .

With erythromycin therapy in DPB , great reduction in bronchiolar inflammation and damage is achieved through suppression of not only neutrophil proliferation , but also lymphocyte activity and obstructive mucus and water secretions in airways . The antibiotic effects of macrolides are not involved in their beneficial effects toward reducing inflammation in DPB . This is evident because the treatment dosage is much too low to fight infection , and in DPB cases with the occurrence of macrolide @-@ resistant *P. aeruginosa* , erythromycin therapy still reduces inflammation .

A number of factors are involved in suppression of inflammation by erythromycin and other macrolides . They are especially effective at inhibiting the proliferation of neutrophils , by diminishing the ability of interleukin 8 and leukotriene B4 to attract them . Macrolides also reduce the efficiency of adhesion molecules that allow neutrophils to stick to bronchiolar tissue linings . Mucus production in the airways is a major culprit in the morbidity and mortality of DPB and other respiratory diseases . The significant reduction of inflammation in DPB attributed to erythromycin therapy also helps to inhibit the production of excess mucus .

= = Prognosis = =

Untreated DPB leads to bronchiectasis , respiratory failure , and death . A journal report from 1983 indicated that untreated DPB had a five @-@ year survival rate of 62 @-@ 1 % , while the 10 @-@ year survival rate was 33 @-@ 2 % . With erythromycin treatment , individuals with DPB now have a much longer life expectancy due to better management of symptoms , delay of progression , and prevention of associated infections like *P. aeruginosa* . The 10 @-@ year survival rate for treated DPB is about 90 % . In DPB cases where treatment has resulted in significant improvement , which sometimes happens after about two years , treatment has been allowed to end for a while . However

, individuals allowed to stop treatment during this time are closely monitored . As DPB has been proven to recur , erythromycin therapy must be promptly resumed once disease symptoms begin to reappear . In spite of the improved prognosis when treated , DPB currently has no known cure .

#### = = Epidemiology = =

DPB has its highest prevalence among the Japanese , at 11 per 100 @, @ 000 population . Korean , Chinese , and Thai individuals with the disease have been reported as well . A genetic predisposition among East Asians is suggested . The disease is more common in males , with the male to female ratio at 1 @. @ 4 ? 2 : 1 ( or about 5 men to 3 women ) . The average onset of the disease is around age 40 , and two @-@ thirds of those affected are non @-@ smokers , although smoking is not believed to be a cause . The presence of HLA @-@ Bw54 increases the risk of diffuse panbronchiolitis 13 @. @ 3 @-@ fold .

In Europe and the Americas , a relatively small number of DPB cases have been reported in Asian immigrants and residents , as well as in individuals of non @-@ Asian ancestry . Misdiagnosis has occurred in the West owing to less recognition of the disease than in Asian countries . Relative to the large number of Asians living in the west , the small number of them thought to be affected by DPB suggests non @-@ genetic factors may play some role in its cause . This rarity seen in Western Asians may also be partly associated with misdiagnosis .

#### = = History = =

In the early 1960s , a relatively new chronic lung disease was being observed and described by physicians in Japan . In 1969 , the name " diffuse panbronchiolitis " was introduced to distinguish it from chronic bronchitis , emphysema , alveolitis , and other obstructive lung disease with inflammation . Between 1978 and 1980 , results of a nationwide survey initiated by the Ministry of Health and Welfare of Japan revealed more than 1 @, @ 000 probable cases of DPB , with 82 histologically confirmed . By the 1980s , it was internationally recognized as a distinct disease of the lungs .

Before the 1980s , the prognosis or expected outcome of DPB was poor , especially in cases with superinfection ( the emergence of a new viral or bacterial infection , in addition to the currently occurring infection ) by *P. aeruginosa* . DPB continued to have a very high mortality rate before generalized antibiotic treatment and oxygen therapy were beginning to be used routinely in the effort to manage symptoms . Around 1985 , when long @-@ term treatment with the antibiotic erythromycin became the standard for managing DPB , the prognosis significantly improved . In 1990 , the association of DPB with HLA was initially asserted .